Hodgkin Lymphoma: A Special Microenvironment

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

(2021) Ron D. Jachimowicz et al.   LEUKEMIA

Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58

(2020) Johanna Veldman et al.   BLOOD

Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

(2020) Lourdes Calvente et al.   BRITISH JOURNAL OF HAEMATOLOGY

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

(2020) Philippe Armand et al.   Blood Advances

Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B‐cell lymphoma

(2020) Benedetta Donati et al.   HEMATOLOGICAL ONCOLOGY

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

(2019) Robert Chen et al.   BLOOD

A Gene Expression–based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients

(2019) Stefano Luminari et al.   CLINICAL CANCER RESEARCH

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies

(2018) Anja Mottok et al.   BLOOD

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

(2017) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma

(2017) Fong Chun Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

(2017) Marco Ruella et al.   Cancer Discovery

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

(2016) A. Kumar et al.   BLOOD

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance

(2016) Donatella Aldinucci et al.   CANCER LETTERS

CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse

(2016) F R Abdul Razak et al.   GENES AND IMMUNITY

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma

(2016) Manuel Gotti et al.   HEMATOLOGICAL ONCOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

(2016) Catherine S. Diefenbach et al.   JNCI-Journal of the National Cancer Institute

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

NF-κB deregulation in Hodgkin lymphoma

(2016) Marc A. Weniger et al.   SEMINARS IN CANCER BIOLOGY

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

(2016) Catherine S. Diefenbach et al.   JNCI-Journal of the National Cancer Institute

How I treat advanced classical Hodgkin lymphoma

(2015) P. Johnson et al.   BLOOD

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

(2015) B. von Tresckow et al.   CLINICAL CANCER RESEARCH

Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome

(2015) Maja D. Andersen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Alterations of theCD58gene in classical Hodgkin lymphoma

(2015) Markus Schneider et al.   GENES CHROMOSOMES & CANCER

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of T cells in the microenvironment of Hodgkin lymphoma

(2015) Frederik Wein et al.   JOURNAL OF LEUKOCYTE BIOLOGY

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

(2015) Alison J Moskowitz et al.   LANCET ONCOLOGY

Mast cells as targets for immunotherapy of solid tumors

(2015) Sharon A. Oldford et al.   MOLECULAR IMMUNOLOGY

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

(2015) Anna Śledzińska et al.   Molecular Oncology

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells

(2014) J. Reichel et al.   BLOOD

The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing

(2014) Y Liu et al.   LEUKEMIA

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells

(2013) P. Greaves et al.   BLOOD

CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma

(2013) Smita Kayal et al.   LEUKEMIA & LYMPHOMA

Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells

(2013) B. Rengstl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component

(2013) Yuxuan Liu et al.   SEMINARS IN CANCER BIOLOGY

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

(2012) K. L. Tan et al.   BLOOD

Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma

(2012) C. Steidl et al.   BLOOD

Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma

(2012) Claudia Otto et al.   BRITISH JOURNAL OF HAEMATOLOGY

Expression of CD137 on Hodgkin and Reed-Sternberg Cells Inhibits T-cell Activation by Eliminating CD137 Ligand Expression

(2012) W. T. Ho et al.   CANCER RESEARCH

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma

(2012) Jonathan A Harris et al.   Diagnostic Pathology

Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma

(2012) David W. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome

(2012) Paul Greaves et al.   JOURNAL OF CLINICAL ONCOLOGY

Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib

(2012) H Mizuno et al.   LEUKEMIA

Differentiation and function of Foxp3+ effector regulatory T cells

(2012) Erika Cretney et al.   TRENDS IN IMMUNOLOGY

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma

(2011) D. Azambuja et al.   ANNALS OF ONCOLOGY

A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix

(2011) Walayat Shah et al.   Cellular & Molecular Immunology

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

(2011) P. Allavena et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment

(2011) Donatella Aldinucci et al.   LEUKEMIA & LYMPHOMA

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Micromilieu of Classical Hodgkin Lymphoma

(2011) Alexandar Tzankov et al.   PATHOBIOLOGY

Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma

(2011) Mona A. A. Zaki et al.   VIRCHOWS ARCHIV

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

(2010) Junliang Ma et al.   BMC CANCER

Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma

(2010) Jonathan R. Fromm   CYTOMETRY PART B-CLINICAL CYTOMETRY

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape

(2010) Donatella Aldinucci et al.   JOURNAL OF PATHOLOGY

Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma

(2010) Björn Lamprecht et al.   NATURE MEDICINE

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathogenesis of Classical and Lymphocyte-Predominant Hodgkin Lymphoma

(2009) Roland Schmitz et al.   Annual Review of Pathology-Mechanisms of Disease

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma

(2009) Lara Cattaruzza et al.   INTERNATIONAL JOURNAL OF CANCER

Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma

(2009) Trine O. Jensen et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells

(2008) Karl R.N. Baumforth et al.   AMERICAN JOURNAL OF PATHOLOGY

IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis

(2008) F. A. Scheeren et al.   BLOOD

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

(2008) B. Chetaille et al.   BLOOD

Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer

(2008) Giuseppe Perrone et al.   EUROPEAN JOURNAL OF CANCER

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation

(2008) Qizhi Tang et al.   NATURE IMMUNOLOGY

HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma

(2008) A. Diepstra et al.   TISSUE ANTIGENS

Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions

(2007) Donatella Aldinucci et al.   INTERNATIONAL JOURNAL OF CANCER